Rein Therapeutics slips on FDA clinical hold for lung disease drug

Rein Therapeutics

13/06/2025 14:57

** Shares of drug developer Rein Therapeutics RNTX.O fall 9.8% to $1.74

** Late on Thursday, the U.S. FDA put a clinical hold on co's mid-stage trial of LTI-03, a lung disease drug - SEC filing

** Patient enrollment and dosing have been paused in the U.S.

** Co said it is working with the FDA to resolve the issue and lift the hold

** The trial is still ongoing in Australia and Europe

** Including session move, stock down 21.7% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))